I believe the trial is being run by the Cleveland Clinic, so timing is somewhat out of MSB’s control.
It is what the company considers as mid-stage, along with the ARDs. Both massive indications as well, and with the right FDA designations and success from these late stage indications, MSB will be able to develop these.
its a pipeline that is quite broad and the funds are limited, and they can’t at this stage dedicate the same funds and resources to everything in their pipeline.
so I believe in the UC opportunity, and an update is likely going to come out of the blue as it isn’t the focus right now (they are focused on late stage assets right now).
goodluck
MSB Price at posting:
55.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)